Drug intelligence / Profile preview

iso-[131I]SGMIB-A345

Development stage
Preclinical
Lead developer
Duke University Medical Center
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

iso-[131I]SGMIB-A345 is a preclinical GPC3-targeted radiopharmaceutical developed by Duke University Medical Center. It consists of the GPC3-specific single-domain antibody fragment (sdAb) A345 conjugated to the radioiodinated residualizing prosthetic agent 1,3,5-[131I]SGMIB (iso-SGMIB). The agent is designed for targeted radionuclide therapy (TRT) of Glypican-3 (GPC3)-expressing malignancies, such as hepatocellular carcinoma and neuroendocrine prostate cancer. A345 can be prepared as a monomer, dimer, or trimer, with multimeric forms demonstrating enhanced binding affinity and cellular internalization in GPC3-positive tumor models.

Other names
1,3,5-[131I]SGMIB-A345iso-[131I]SGMIB-A345-dimeriso-[131I]SGMIB-A345-monomeriso-[131I]SGMIB-A345-trimer
02

Targets

GPC3 (Glypican-3)

Beyond the preview

Go deeper on iso-[131I]SGMIB-A345.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on iso-[131I]SGMIB-A345.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call